JP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $695
JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and lowers the price target from $710 to $695.
Share
Why It Matters
A big bank analyst still likes United Therapeutics overall. But they lowered their guess for where the stock could go.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.